Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA hits pause on COVID-19 vaccine for children under 5

By Brian Buntz | February 11, 2022

FDA logoFDA may wait several months before deciding to authorize a COVID-19 vaccine for children between the ages of 6 months to 4 years.

The agency had planned on adjourning a meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 15 to discuss the potential use of the vaccine in younger children.

But FDA decided to postpone the meeting until further notice after Pfizer (NYSE:PFE) shared new data related to its emergency use authorization (EUA) request for an ongoing clinical trial testing the Pfizer-BioNTech vaccine in young children.

FDA indicated in a statement that it wants to review data related to a third dose of the vaccine to foster “a transparent public discussion as part of our usual scientific and regulatory processes for COVID-19 vaccines.”

The agency noted that evaluating initial data from the clinical trial was “useful.” But FDA believes “additional information regarding the ongoing evaluation of a third dose should be considered,” explained Acting FDA Commissioner Dr. Janet Woodcock and Dr. Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research.

Pfizer-BioNTech vaccine

Image courtesy of Wikimedia Commons.

The agency will confirm the timing for the next VRBPAC meeting after receiving more data from the ongoing clinical study.

Pfizer and BioNTech announced in a statement that they had decided to extend the rolling submission for an amended EUA for young children until more data are available.

The companies have committed to providing ongoing data from a clinical trial involving children aged 6 months to 4 years with the agency.

Before the announcement, CDC had instructed COVID-19 vaccine providers to prepare for vaccinating children under the age of 5 by Feb. 21.

The independent Data Monitoring Committee (DMC) monitoring the clinical trial for the COVID-19 vaccine favors continuing the trial, which could potentially support a three-dose schedule of the vaccine.


Filed Under: Infectious Disease
Tagged With: BioNTech, COVID-19 vaccine, FDA, Pfizer, Vaccines and Related Biological Products Advisory Committee, VRBPAC
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Bavarian Nordic
U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
covid-19 vaccine
FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Icosavax
Icosavax shares positive early results for VLP vaccine candidate against RSV

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50